Screener
PTC Therapeutics PTCT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Proceeds from exercise of options | $6,403 | $15,751 |
| Payments on contingent consideration obligation | — | (6,341) |
| Net cash provided by financing activities | $6,403 | $9,410 |
| Effect of exchange rate changes on cash | (1,524) | 5,393 |
| Net (decrease) increase in cash and cash equivalents | (147,899) | 700,546 |
| Cash and cash equivalents, and restricted cash beginning of period | 998,334 | 795,316 |
| Cash and cash equivalents, and restricted cash end of period | $850,435 | $1,495,862 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's financing cash flow?
- PTC Therapeutics (PTCT) reported financing cash flow of $6.4M in Q1 2026.
- How has PTC Therapeutics's financing cash flow changed year-over-year?
- PTC Therapeutics's financing cash flow decreased by 32.0% year-over-year, from $9.41M to $6.4M.
- What is the long-term trend for PTC Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), PTC Therapeutics's financing cash flow has grown at a 99.6% compound annual growth rate (CAGR), from $20.88M to $331.09M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about PTC Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude